Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze RNST stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate RNST investment potential.

What is RNST stock price today?

Get real-time RNST stock price, historical data, and price charts on Financhill. Track RNST performance with our advanced analysis tools.

Is RNST a good investment?

Evaluate RNST investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy RNST stock?

To buy RNST stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of RNST?

View detailed market capitalization data and company valuation metrics for RNST on our comprehensive analysis page.

What is the P/E ratio of RNST?

Use our fundamental analysis tools to view RNST P/E ratio and compare valuation metrics with industry peers.

What are RNST earnings?

View RNST earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Renasant Corp. 10K Form

Buy

RNST
Renasant Corp.

Last Price:

$37.03

Seasonality Move:

8.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08	10Q	RNST/Renasant Corp. Quarterly
2023-11-08	10Q	RNST/Renasant Corp. Quarterly
2023-08-04	10Q	RNST/Renasant Corp. Quarterly
2023-05-08	10Q	RNST/Renasant Corp. Quarterly
2022-11-04	10Q	RNST/Renasant Corp. Quarterly
2022-08-08	10Q	RNST/Renasant Corp. Quarterly

Receive RNST News And Ratings

See the #1 stock for the next 7 days that we like better than RNST

RNST Financial Statistics

Sales & Book Value

Annual Sales:	$1.4B
Cash Flow:	$103.8M
Price / Cash Flow:	13.66
Annual Sales:	$41.05
Price / Book:	0.89

Profitability

EPS (TTM):	2.11610
Net Income (TTM):	$181.3M
Gross Margin:	$0
Return on Equity:	5.37%
Return on Assets:	0.78%

Renasant Corp. Earnings Forecast

Key Renasant Corp. Financial Ratios

The Gross Profit Margin over the past 37 years for RNST is 0.00%.
The Selling, General & Administrative Expenses for RNST have been equal to 0.00% of Gross Profit Margin.
The Interest Expense is 25.23% of Operating Income.
The Net Earning history of RNST is 12.56% of Total Revenues.
Per Share Earnings over the last 37 years have been positive in 20 years.

Renasant Corp. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NYSE
Industry:	Banks
Sector:	Financials
Current Symbol:	RNST
CUSIP:	75970E
Website:	renasant.com

Debt

Debt-to-Equity Ratio:	0.29
Current Ratio:	0.06
Quick Ratio:	0

Price-to-Earnings

Trailing P/E Ratio:	17.94
Forward P/E Ratio:	9.66

RNST Technical Analysis vs Fundamental Analysis

Buy

Renasant Corp. (RNST) is a Buy

Is Renasant Corp. a Buy or a Sell?

Renasant Corp. stock is rated a Buy

The current Renasant Corp. [RNST] share price is $37.03. The Score for RNST is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.